This year's event in Shanghai has now come to an end. It's been a great couple of days, including the IP Asia Elite Gala Dinner and Awards held last night
How Chinese courts will rule the patent world; Qualcomm's 5G licensing spree; don't jail trolls, says former supreme court judge; patent sales are on the up; plus a whole lot more from a wet, but spectacular, Shanghai Pudong
Your essential Sunday reading: a summary of all the stories posted on the IAM platform in the past week - as well as links to each one
Previous FRAND-related rulings indicate judges in China could set a global rate, would adopt the hard-edged non-discrimination obligation and would consider the parties' negotiation behaviours when reaching their decisions
There is not much time left to make nominations for the 2019 edition of IAM Strategy 300, our exclusive guide on the world's best IP strategists.
TCL v Ericsson and Unwired Planet v Huawei send two very different messages to auto companies being approached by patent pools such as Avanci to take SEP licences, says Unified Patents' chief IP counsel Jonathan Stroud
Life sciences IP is on the front line as American consumers, legislators and the Trump administration kick back against the high cost of medicines. Reform campaigners say they have never been more confident of change.
Exclusive analysis done by ROL Group for IAM shows a maturing market in which prices are stabilising, selling programmes are becoming more streamlined and there are more transactions overall
Justices today considering a much-anticipated case whose outcome could make it harder for pharma companies to obtain such protection in the future
Tipped to be the ranking Republican on the House Judiciary Committee, Doug Collins looks set to emerge as one of most powerful IP policy voices on Capitol Hill
Firms like iPEL are creating a buzz in the country's patent market, but as of yet there are few indications that Beijing will roll out the welcome mat
Cannabis patent war looming, “New NAFTA” set to benefit biopharma innovators, a blow for medical device inventors at the CJEU, and much more in this round-up of October’s big life sciences IP news
Company now faces possibility of £500 million pay-out to the NHS, while ruling could also make second medical use patents harder to obtain and easier to invalidate
Matthew Whitaker (right) allegedly sent intimidating emails to victims of World Patent Marketing, a firm that was shut down by the FTC and fined $26 million for cheating inventors.